• Investors
  • Contact
Iconovo
  • About us
    • Board of Directors
    • Management
    • Our Team
    • Sustainability
    • Career
  • Inhalers
    • ICOcap®​
    • ICOpre®​
    • ICOres®
    • ICOone®​
    • ICOone®​ Nasal
  • Development capabilities
    • Inhalers
    • Formulation
    • Pharmaceutical Analysis
  • Pipeline
  • News & Events
  • Partner with us

Analyst coverage

  • The Share
    • Insiders
    • Analyst coverage
    • Largest shareholders
    • Historical capital raisings
  • Press Releases
  • Financial reports
  • Financial calendar
  • Financial presentations
  • Corporate governance
    • Auditor and certified adviser
    • Board of Directors
    • Corporate documents and policies
    • General meetings
    • Management
    • Nomination committee

Our Analysts

Danske Bank

Lars Hevreng

lars.hevreng@danskebank.se

Caroline Banér

caroline.baner@danskebank.se


DNB Carnegie Investment Bank 

Maria Karlsson Osipova

maria.karlsson.osipova@dnbcarnegie.se

Commissioned analysis, DNB Carnegie Access

See all the latest analysis and publications >>

Experts in inhalation medicine

Iconovo develops inhalation medicines in strategic partnership with other pharmaceutical companies. Combining our diverse portfolio of patented dry powder inhalers with considerable drug formulation expertise, we have the capacity for end-to-end product development in this area.

Iconovo AB

Visiting address
Ideon, Delta 6 LUND
Ideongatan 3B

Postal address
Iconovo AB
Ideongatan 3A-B
SE-223 62 LUND
Sweden

Press releases
Subscription
Follow us
  • LinkedIn

Copyright Iconovo AB - All Rights Reserved